Eculizumab in Shiga toxin-producing Escherichia coli hemolytic uremic syndrome: a systematic review

• Published in: Pediatric nephrology (Berlin, West) Vol. 39; no. 5; pp. 1369 - 1385
• Main Authors: de Zwart, Paul L., Mueller, Thomas F., Spartà, Giuseppina, Luyckx, Valerie A.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.05.2024; Springer Nature B.V
• Subjects: Antibodies, Monoclonal, Humanized - therapeutic use; Bacterial infections; Child; Clinical trials; Complement activation; Complement Inactivating Agents - therapeutic use; E coli; Escherichia coli Infections - complications; Escherichia coli Infections - drug therapy; Escherichia coli Infections - microbiology; Hemolytic uremic syndrome; Hemolytic-Uremic Syndrome - drug therapy; Hemolytic-Uremic Syndrome - microbiology; Humans; Medicine; Medicine & Public Health; Morbidity; Nephrology; Patients; Pediatrics; Population studies; Seizures; Shiga toxin; Shiga-Toxigenic Escherichia coli - isolation & purification; Statistical analysis; Systematic review; Systematic Review/Meta-analysis; Treatment Outcome; Urology; Eculizumab; Typical HUS; Hemolytic uremic syndrome; HUS; Infection-associated
• ISSN: 0931-041X; 1432-198X; 1432-198X
• DOI: 10.1007/s00467-023-06216-1

Background Infection-associated hemolytic uremic syndrome (IA-HUS), most often due to infection with Shiga toxin-producing bacteria, mainly affects young children. It can be acutely life-threatening, as well as cause long-term kidney and neurological morbidity. Specific treatment with proven efficacy is lacking. Since activation of the alternative complement pathway occurs in HUS, the monoclonal C5 antibody eculizumab is often used off-label once complications, e.g., seizures, occur. Eculizumab is prohibitively expensive and carries risk of infection. Its utility in IA-HUS has not been systematically studied. This systematic review aims to present, summarize, and evaluate all currently available data regarding the effect of eculizumab administration on medium- to long-term outcomes (i.e., outcomes after the acute phase, with a permanent character) in IA-HUS. Methods PubMed, Embase, and Web of Science were systematically searched for studies reporting the impact of eculizumab on medium- to long-term outcomes in IA-HUS. The final search occurred on March 2, 2022. Studies providing original data regarding medium- to long-term outcomes in at least 5 patients with IA-HUS, treated with at least one dose of eculizumab during the acute illness, were included. No other restrictions were imposed regarding patient population. Studies were excluded if data overlapped substantially with other studies, or if outcomes of IA-HUS patients were not reported separately. Study quality was assessed using the ROBINS-I tool for risk of bias in non-randomized studies of interventions. Data were analyzed descriptively. Results A total of 2944 studies were identified. Of these, 14 studies including 386 eculizumab-treated patients met inclusion criteria. All studies were observational. Shiga toxin-producing E. coli (STEC) was identified as the infectious agent in 381 of 386 patients (98.7%), effectively limiting the interpretation of the data to STEC-HUS patients. Pooling of data across studies was not possible. No study reported a statistically significant positive effect of eculizumab on any medium- to long-term outcome. Most studies were, however, subject to critical risk of bias due to confounding, as more severely ill patients received eculizumab. Three studies attempted to control for confounding through patient matching, although residual bias persisted due to matching limitations. Discussion Current observational evidence does not permit any conclusion regarding the impact of eculizumab in IA-HUS given critical risk of bias. Results of randomized clinical trials are eagerly awaited, as new therapeutic strategies are urgently needed to prevent long-term morbidity in these severely ill patients. Systematic review registration number OSF Registries, MSZY4, Registration DOI https://doi.org/10.17605/OSF.IO/MSZY4 .